Clinical Trials Logo

Liver Diseases clinical trials

View clinical trials related to Liver Diseases.

Filter by:

NCT ID: NCT04924595 Enrolling by invitation - Liver Diseases Clinical Trials

Exercise Intervention in Liver Transplant Candidates

Start date: April 25, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to investigate the effect of personalised exercise interventions in liver transplant candidates, aiming to prevent or limit sarcopenia and frailty, as well as improving their cardiorespiratory health.

NCT ID: NCT04896723 Not yet recruiting - Liver Cirrhosis Clinical Trials

Sexual Dysfunction in Patients With Chronic Liver Disease

Start date: June 1, 2021
Phase:
Study type: Observational

This project will determine the incidence of sexual dysfunction in patients with chronic liver disease, through questionnaires. The questionnaires have been designed to assess several facets of sexual health, e.g. libido, physical symptoms, depression, etc. 150 patients in our liver outpatient department, and 150 healthy volunteers will be asked to fill in the questionnaire in paper form. The results of this project will be used to produce patient resources, advice sheets and educational materials for patients with chronic liver disease. There is also scope to consider possible interventions in the future to improve sexual dysfunction in patients with chronic liver disease.

NCT ID: NCT04883177 Completed - COVID-19 Clinical Trials

Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

Start date: May 11, 2021
Phase:
Study type: Observational

COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver disease are more susceptible to damage from SARS-CoV-2 infection considering their immunocompromised status. Therefore, early inoculation of SARS-CoV-2 vaccine in patients with liver disease is an important protective measure. However, information on the effectiveness and safety of the COVID-19 vaccine for liver disease remains to be determined. This muilticentre study (CHESS2101) aims to study the effectiveness and safety of the COVID-19 vaccination for patients with liver disease.

NCT ID: NCT04873609 Completed - Hepatitis C Clinical Trials

Electronic Record Assimilation and Subsequent Eradication of Hepatitis C

ERASE-C
Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Given the disproportionately high risk of chronic hepatitis C virus (HCV) infection in the baby boomer cohort, population-based screening has been demonstrated cost effective. Compared to point-of-care testing, however, bulk health messages with coupled lab requisitions delivered directly to patients meeting screening criteria via patient portals could improve HCV screening at minimal cost.

NCT ID: NCT04863144 Recruiting - Liver Diseases Clinical Trials

Pharmacokinetics of Paclitaxel in Correlation With Adverse Events in Cancer Patients With and Without Liver Impairment

Start date: August 1, 2020
Phase:
Study type: Observational

The study aims to assess the pharmacokinetics of paclitaxel and its two major metabolites in patients with normal and impaired liver functions.

NCT ID: NCT04826666 Completed - Surgery Clinical Trials

Intraoperative Phlebotomies and Bleeding in Liver Transplantation

TOF_PHLEBO
Start date: March 31, 2021
Phase:
Study type: Observational

Liver transplantation are surgeries associated with important bleeding and often require perioperative red blood cell (RBC) transfusions. Overall, between 20 and 85 % of liver transplant recipients receive at least one RBC transfusion during their surgery. Such transfusions are consistently associated with higher morbidity and mortality, although this causal association is still under debate in many surgical populations. Despite the lack of clear causative association between perioperative transfusions and worse outcomes, minimizing bleeding and transfusions is believed to improve postoperative outcomes. Many perioperative variables are associated with higher blood loss and need for perioperative transfusions: liver disease severity, preoperative anemia and coagulopathy, higher cardiac filling pressures and higher fluid administration, among others. However, few perioperative interventions have been shown to reduce bleeding and transfusion requirements in this population. Among them, the use of intraoperative phlebotomies to reduce portal and hepatic venous pressure during the dissection phase is a promising one, also described in liver resection surgery. To further investigate the effects of intraoperative phlebotomies on intraoperative bleeding, perioperative transfusions and mortality, the Principal Investigator will conduct a retrospective cohort study with a propensity score based causal analysis.

NCT ID: NCT04825470 Not yet recruiting - Liver Cancer Clinical Trials

Liver Transplantation for Unresectable GIST Liver Metastases

TRANSGIST
Start date: May 2022
Phase: N/A
Study type: Interventional

Liver Transplantation for Unresectable GIST Liver Metastases

NCT ID: NCT04816682 Completed - Covid19 Clinical Trials

Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes

SILCOVINT-21
Start date: March 17, 2021
Phase: Phase 4
Study type: Interventional

Of patients admitted to an internal medicine ward with internistic diagnosis/es together with COVID-19, substantial proportion has elevated liver enzymes. silymarin / silibinin (milk thistle extract) has been approved as an add-on therapy in various acute and chronic liver diseases; moreover, there is evidence to suggest that it's dual effect (anti-viral and immune-modulatory) might be of benefit in patients infected with SARS-CoV-2. As there is no effective/approved pharmacotherapy for COVID-19, a pilot study with Silymarine in hospitalised patients has been undertaken

NCT ID: NCT04789213 Completed - Liver Cirrhosis Clinical Trials

Mortality, Morbidity and Risk Factors of Liver Retransplantation

Start date: March 10, 2021
Phase:
Study type: Observational

This study aims to compare the short and long term outcomes of living donor and deceased donor liver retransplantation. Bearing that in mind, the investigators will retrospectively analyze the files of patients whom underwent a liver retransplantation in Memorial Bahcelievler Hospital Organ Transplantation Center.

NCT ID: NCT04782050 Completed - Liver Cirrhosis Clinical Trials

Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation

DIACEPA
Start date: September 15, 2021
Phase: N/A
Study type: Interventional

Early screening and monitoring of chronic liver diseases in hepatology practice has become crucial. To achieve this goal, hepatology clinics need simple and available tools at the point-of-care to perform disease severity assessment. The objective of this study is to assess the performance of a new non-invasive ultrasound-based system for the assessment of liver fibrosis and steatosis severity, via ultrasound biomarkers such as tissue stiffness (correlated to fibrosis severity) and ultrasound tissue attenuation (correlated to steatosis extent).